Welche okkulte axilläre Tumorlast ist bei Verzicht auf eine komplettierende Axilladissektion unter Berücksichtigung der ACOSOG-Z0011-Einschlusskriterien in der Routine zu erwarten?

• Literatur

• 1 Riedel F, Heil J, Golatta M. et al. Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade. Arch Gynecol Obstet 2019; 299: 1043-1053
• 2 Giuliano AE, Hunt KK, Ballman KV. et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011; 305: 569-575
• 3 Hennigs A, Kopke M, Feisst M. et al. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?. Breast Cancer Res Treat 2019; 173: 429-438
• 4 Riedel F, Heil J, Feisst M. et al. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. Breast Cancer Res Treat 2019; 177: 457-467
• 5 Hennigs A, Riedel F, Marme F. et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat 2016; 160: 491-499
• 6 Hennigs A, Riedel F, Feisst M. et al. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study. Ann Surg Oncol 2019; 26: 2435-2443